Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9thBOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced its abstract highlighting immune mechanism-of-action data for its novel ADC payload, PH1. The abstract is now available on the 40th Annual SITC Meeting website, and the Company will present th ...